Muñoz M, Botella-Romero F, Gómez-Ramírez S, Campos A, García-Erce J A
School of Medicine, University of Málaga, Málaga, Spain.
Nutr Hosp. 2009 Nov-Dec;24(6):640-54.
Obesity-induced chronic inflammation leads to activation of the immune system that causes alterations of iron homeostasis including hypoferraemia, iron-restricted erythropoiesis, and finally mild-to-moderate anaemia. Thus, preoperative anaemia and iron deficiency are common among obese patients scheduled for bariatric surgery (BS). Assessment of patients should include a complete haematological and biochemical laboratory work-up, including measurement of iron stores, vitamin B12 and folate. In addition, gastrointestinal evaluation is recommended for most patients with iron-deficiency anaemia. On the other hand, BS is a long-lasting inflammatory stimulus in itself and entails a reduction of the gastric capacity and/or exclusion from the gastrointestinal tract which impair nutrients absorption, including dietary iron. Chronic gastrointestinal blood loss and iron-losingenteropathy may also contribute to iron deficiency after BS. Perioperative anaemia has been linked to increased postoperative morbidity and mortality and decreased quality of life after major surgery, whereas treatment of perioperative anaemia, and even haematinic deficiency without anaemia, has been shown to improve patient outcomes and quality of life. However, long-term follow-up data in regard to prevalence, severity, and causes of anaemia after BS are mostly absent. Iron supplements should be administered to patients after BS, but compliance with oral iron is no good. In addition, once iron deficiency has developed, it may prove refractory to oral treatment. In these situations, IV iron (which can circumvent the iron blockade at enterocytes and macrophages) has emerged as a safe and effective alternative for perioperative anaemia management. Monitoring should continue indefinitely even after the initial iron repletion and anaemia resolution, and maintenance IV iron treatment should be provided as required. New IV preparations, such ferric carboxymaltose, are safe, easy to use and up to 1000 mg can be given in a single session, thus providing an excellent tool to avoid or treat iron deficiency in this patient population.
肥胖诱导的慢性炎症会导致免疫系统激活,进而引起铁稳态改变,包括低铁血症、铁限制的红细胞生成,最终导致轻至中度贫血。因此,术前贫血和缺铁在计划接受减重手术(BS)的肥胖患者中很常见。对患者的评估应包括完整的血液学和生化实验室检查,包括铁储备、维生素B12和叶酸的测定。此外,对于大多数缺铁性贫血患者,建议进行胃肠道评估。另一方面,BS本身就是一种长期的炎症刺激,会导致胃容量减少和/或胃肠道排除,从而损害营养物质的吸收,包括膳食铁。慢性胃肠道失血和失铁性肠病也可能导致BS后缺铁。围手术期贫血与术后发病率和死亡率增加以及大手术后生活质量下降有关,而围手术期贫血的治疗,甚至是无贫血的造血物质缺乏的治疗,已被证明可以改善患者的预后和生活质量。然而,关于BS后贫血的患病率、严重程度和原因的长期随访数据大多缺乏。BS术后应给患者补充铁剂,但口服铁剂的依从性不佳。此外,一旦出现缺铁,口服治疗可能无效。在这些情况下,静脉注射铁剂(可以绕过肠细胞和巨噬细胞的铁阻断)已成为围手术期贫血管理的一种安全有效的替代方法。即使在最初的铁补充和贫血缓解后,监测也应无限期持续,并应根据需要提供维持性静脉注射铁剂治疗。新的静脉注射制剂,如羧基麦芽糖铁,安全、易用,单次给药可达1000mg,因此为避免或治疗该患者群体的缺铁提供了一个极好的工具。